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Abstract
Background: Triple-negative breast cancer (TNBC) is known for aggressive biologic features and poor prognosis.
Epidermal growth factor receptor (EGFR) overexpression in TNBC indicates poor prognosis. However, there is no
previous study of the relationship between expression of the entire human epidermal growth factor receptor (HER)
family genes and patient prognosis in TNBC. Accordingly, we investigated the expression profiles of HER family
genes in patients with TNBC to determine the prognostic value and clinical implications of HER family expression.
Methods: We used the nCounter expression assay (NanoString®) to measure the expression of EGFR, erb-B2 receptor
tyrosine kinase 2 (ERBB2), ERBB3, ERBB4, and estrogen receptor 1 (ESR1) genes using mRNA extracted from
paraffin-embedded tumor tissues from 203 patients diagnosed with TNBC. Our data were validated using a
separate cohort of 84 TNBC patients.
Results: A total of 203 TNBC patients who received adjuvant chemotherapy after curative surgery from 2000 to
2004 formed the training set. The 84 TNBC patients in the validation consort were selected from breast cancer
patients who received curative surgery since 2005 to 2010. Analysis of the expression profiles of the HER family
genes in TNBC tissue specimens revealed that increased expression of ERBB4 was associated with poor prognosis
according to survival analysis (5-year distant relapse free survival [5Y DRFS], low vs. high expression [cut-off: median]:
90.1 % vs. 80.2 %; p = 0.022). This trend was also observed in the validation set of TNBC patients (5Y DRFS, low vs. high:
69.4 % vs. 44.7 %; p = 0.053). In a multivariate Cox regression model, ERBB4 expression was identified as a indicator of
long-term prognosis in patients with TNBC.
Conclusions: The expression profile of ERBB4, a member of the HER family, might serve as a prognostic marker in
patients with TNBC.
Keywords: ERBB4, Triple negative breast cancer, nCounter expression assay
Background
Triple negative breast cancer (TNBC), defined as the ab-
sence of both hormone receptor expression and erb-B2
receptor tyrosine kinase 2 (ERBB2) overexpression, ac-
counts for approximately 15-20 % of all breast cancers
[1]. In general, TNBC is diagnosed at a higher stage and
has more aggressive biologic features and worse progno-
sis than other subtypes [2, 3].
Overexpression of the human epidermal growth factor
receptor (HER) family members, consisting of epidermal
growth factor receptor (EGFR), ERBB2, ERBB3, and ERBB4,
is frequently observed in many kinds of human epithelial
malignancies [4]. Of the four HER family members, ERBB2
overexpression is known to induce carcinogenesis in
mammalian cells [5, 6]. ERBB2 overexpression is found
in 15-20 % of breast cancers and defines a unique subtype
of breast cancer [7]. Indeed, ERBB2 overexpression is the
therapeutic target for the monoclonal antibodies trastuzu-
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In addition to the known role of ERBB2, research on
other HER family genes in breast cancer is now ongoing.
According to previous research, overexpression of EGFR,
ERBB2, and ERBB3 is associated with poor prognosis
and negatively correlated with estrogen receptor (ER)
expression in breast cancer [12, 13].
In terms of ERBB4, intracellular domain 4ICD of
ERBB4 promotes apoptosis of breast cancer cells and
cytosolic expression of 4ICD is associated with good
prognosis [14, 15]. Moreover, ERBB4 expression is sig-
nificantly related to levels of phospho-AKT and ERK in
TNBC as a good prognostic factor [16]. Another study
reported that ERBB4 expression is positively related to
ER-positive breast cancer [17–19]. Patients with breast
cancer showing co-expression of ERBB4 and ER have
fewer recurrences and improved survival compared to
patients diagnosed with ER-positive breast cancer with-
out ERBB4 expression [20, 21].
Some studies have found that EGFR overexpression in-
dicates poor prognosis in TNBC [22, 23]. In preclinical
studies, EGFR overexpression was detected more fre-
quently and at higher levels in TNBC cell lines than in
other subtypes and the combination of an EGFR target-
ing agent and cytotoxic agent inhibited cell growth more
effectively than cytotoxic chemotherapy alone [24]. The
results of phase I/II clinical trials of cetuximab, a monoclo-
nal antibody targeting EGFR overexpression, demonstrated
clinical benefit in TNBC with EGFR overexpression
[25–27]. However, there are no clear data supporting
the clinical significance of expression of the entire HER
family genes in TNBC.
Accordingly, we determined how the mRNA expres-




This study was a retrospective analysis of the clinical re-
cords of patients with invasive breast cancer who received
adjuvant chemotherapy after curative surgery at Samsung
Medical Center between 2000 and 2004. Women who were
diagnosed with breast cancer at stage I to IIIC by diagnostic
examination (breast magnetic resonance imaging [MRI],
abdominal computed tomography [CT] scan, bone scan,
and/or positron emission tomography [PET]-CT scans if in-
dicated) were included in the training cohort. To validate
our data, we retrospectively reviewed clinical records of
breast cancer patients who received curative surgery at
Samsung Medical Center from 2005 to 2010.
The institutional review board of Samsung Medical
Center, Seoul, Korea approved our study protocol and
waived the need for informed consent due to this study
was conducted using archival tissues with retrospective
clinical data (IRB No: 2012-08-065).
Immunohistochemistry and RNA extraction
We obtained all available hematoxylin and eosin (H&E)-
stained slides of archival formalin-fixed, paraffin-embedded
(FFPE) primary breast tumor tissue samples. Two inde-
pendent pathologists reviewed all pathology specimens to
determine tumor histologic characteristics (histological
grade [28] and nuclear grade) and immunohistochemical
(IHC) findings (ER and progesterone receptor [PgR] ex-
pression and ERBB2 overexpression). ER and PgR positivity
were defined using Allred scores ranging from 3 to 8 based
on IHC using antibodies to ER (Immunotech, Marseille,
France) and PgR (Novocastra Laboratories Ltd., Newcastle
upon Tyne, UK). HER2 status was evaluated using a spe-
cific antibody (Dako, Glostrop, Denmark) and/or silver in
situ hybridization (SISH). Grades 0 and 1 for ERBB2, as
assessed by IHC, were defined as a negative result, and
grade 3 was defined as a positive result. Amplification
of ERBB2 was confirmed by SISH if ERBB2 was rated
as 2+ by IHC. TNBC was defined as a negative result
for ER/PgR and ERBB2.
RNA was extracted from 2–4 sections of 4-μm thick
FFPE sections containing more than 75 percent of tumor
cells in tumor tissue using the High Pure RNA Paraffin
kit (Roche Diagnostic, Mannheim, Germany). RNA yield
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Fig. 1 Patient cohort (N = 203)
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Table 1 Baseline characteristics of patient cohorts
Training
N = 203 (%)
Validation
N = 84 (%)
p-value
Age (median) 46.4 ± 10.2 46.1 ± 11.0 0.308
Range 23.5-74.1 22.4 – 74.0
< 40 years 48 (23.6) 28 (33.3)
≥ 40 years 155 (76.4) 56 (66.7)
Histology 0.654
IDCa 180 (88.7) 76 (90.5)
Others 23 (11.3) 8 (9.5)
Stage <0.001
I 55 (27.1) 15 (17.9)
IIA 94 (46.3) 18 (21.4)
IIB 33 (16.3) 9 (11.9)
IIIA 13 (6.4) 26 (31.0)
IIIB 0 (0) 1 (1.2)
IIIC 8 (3.9) 14 (16.7)
Unknown 0 (0) 1 (1.2)
Nuclear grade 0.191
1 2 (1.0) 0 (0)
2 47 (23.2) 18 (21.4)
3 145 (71.4) 57 (67.9)
Unknown 9 (4.4) 9 (10.7)
Histologic grade 0.411
1 3 (1.5) 1 (1.2)
2 45 (22.2) 20 (23.8)
3 144 (70.9) 54 (64.3)
Unknown 11 (5.4) 9 (10.7)
RNA expression (log2 scale, median)
EGFR 7.0 ± 1.1 7.6 ± 1.2 0.456
ERBB2 9.0 ± 1.0 9.4 ± 1.6 0.439
ERBB3 7.2 ± 1.0 7.7 ± 1.0 0.503
ERBB4 1.3 ± 1.4 2.3 ± 2.2 0.302
ESR1 4.4 ± 0.1 4.5 ± 2.0 0.425
Chemotherapy NA
Adjuvant 203 (100) 60 (71.4)
Neoadjuvant 0 (0) 24 (28.6)
Unknown 0 (0) 0 (0)
Regimen NA
CMF1 86 (42.4) 10 (11.9)
FAC2 58 (28.6) 16 (19.0)
AC3 17 (8.4) 5 (6.0)
AC –T(H)4 41 (20.2) 46 (54.8)
Hormone 0 (0) 0 (0)
Unknown 1 (0.5) 7 (8.3)
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and purity were assessed using a NanoDrop ND-1000
Spectrophotometer (NanoDrop Technologies, Rockland,
DE, USA). Samples with total RNA concentration < 50 ng/
μL were excluded from analysis because 200 ng of input
RNA in a 5 μL volume was needed for hybridization with
20 μL of probe set master mix.
nCounter expression assay (NanoString®)
The NanoString nCounter Analysis System (NanoString
Technologies, Seattle, WA, USA) was used to measure
gene expression. This system measures the relative
abundance of each mRNA transcript via a multiplexed
hybridization assay and digital readouts of fluorescent
probes [29]. We used an nCounter CodeSet (NanoString
Technologies) containing biotinylated capture probes for
the EGFR, ERBB2, ERBB3, ERBB4, and ESR1 genes and
five housekeeping genes and reporter probes attached to
color barcode tags, according to the nCounterTM code-
set design. These were hybridized in solution to 200 ng
of total RNA for 18 h at 65 °C according to the manu-
facturer’s instructions.
Hybridized samples were loaded into the nCounter
Prep Station for post-hybridization processing. Hybrid-
ized samples were purified and immobilized on the deck
of the Prep Station in a sample cartridge for data collec-
tion, and target mRNA was quantified in each sample
using the nCounterTM Digital Analyzer. Quantified ex-
pression data were analyzed using NanoString nSolver
Analysis Software.
After performing image quality control using a prede-
fined cutoff value, we excluded outlier samples using a
normalization factor based on the sum of positive con-
trol counts greater than threefold. The counts of the
probes were then normalized using the geometric mean
of the five housekeeping genes and log2 transformed for
further analysis.
Statistical analysis
Differences in clinicopathologic characteristics were ana-
lyzed using Student’s t-test for continuous variables and
Pearson chi-square test for categorical variables. Distant
relapse-free survival (DRFS) was defined as the elapsed
time from the date of curative surgery to the detection
of distant relapse of breast cancer. DRFS was analyzed
by the Kaplan-Meier (KM) method. Univariate and
multivariate analyses of DRFS were performed using
Cox’s proportional hazards regression tests. To evaluate re-
lationships among the expression levels of the five genes,
we used Pearson correlation analysis. Finally, receiver oper-
ating characteristic (ROC) analysis was performed to evalu-
ate the prognostic value of the level of gene expression.
ROC analysis was conducted using weighted variables that
were significantly associated with prognosis in previous uni-
variate and multivariate analysis. Weighting of variables
was performed using the hazard ratio in multivariate ana-
lysis. Two-tailed p values <0.05 were considered statistically
significant, and IBM SPSS Statistics 21 for Windows (IBM
Corp., Armonk, NY, USA) was used to analyze all data.
Remark guidelines
In reporting our study, we have adhered to the guidelines















Fig. 2 Heatmap for HER family and ESR1 gene expression. a Training set (N = 203); b Validation set (N = 84)
Table 1 Baseline characteristics of patient cohorts (Continued)
Adjuvant RTx5 0.161
Yes 130 (64.0) 61 (72.6)
No 73 (36.0) 23 (27.4)
aInvasive ductal carcinoma, 1Cyclophosphamide/Methotrexate/Fluorouracil, 2Fluorouracil/Adriamycin/Cyclophosphamide, 3Adriamycin/Cyclophosphamide, 4Taxane
(Herceptin), 5Radiotherapy
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“Reporting recommendations for tumor marker prognostic
studies (REMARK guidelines) [30].” To decrease any po-
tential bias arising from a review of the medical records, we
included “Patient Cohort” analysis to fulfill these cri-
teria (Fig. 1).
Results
Baseline characteristics of patients
A total of 203 patients with TNBC were included in the
training cohort (Fig. 1). In addition, 84 patients with
TNBC were retrospectively included in a validation cohort.
This validation cohort was composed of patients diagnosed
with invasive breast cancer who received curative surgery
from 2005 to 2010, regardless of chemotherapy status.
The baseline characteristics of patients in the training
and validation cohorts are presented in Table 1. In the
training cohort, the median age at diagnosis of breast
cancer was 46.4 years (range, 23.5-74.1). Most patients
were diagnosed with invasive ductal carcinoma (IDC)
(88.7 %) and stage I-II disease (27.1 % as stage I and
62.6 % as stage II).
The baseline characteristics were similar in training
and validation cohorts. However, the patients in the val-
idation cohort had a higher stage of breast cancer than
those in the training cohort (p < 0.001).
Gene expression profile of HER family genes and the
ESR1 gene
The expression profiles of HER family genes and the
ESR1 gene are presented in Fig. 2. Even within TNBC,
each tumor sample had a distinct expression profile.
However, the results of the nCounter expression assay
showed that the level of EGFR, ERBB2, ERBB3, ERBB4,
and ESR1 expression was similar in the training and val-
idation cohorts (Table 1).
We also found that TNBC in the training and validation
cohorts had lower expression of ERBB2, ERBB3, ERBB4,
and ESR1 than non-TNBC subtypes with statistical
Table 2 Impact of baseline characteristics on patient prognosis
in the training cohort (N = 203)
Training





Age (median) 46.4 ± 10.2
Range 23.5-74.1 0.633
< 40 years 48 (23.6) 81.2
≥ 40 years 155 (76.4) 86.4
Histology 0.507
IDCa 180 (88.7) 85.5
Others 23 (11.3) 82.9
Stage <0.001
I 55 (27.1) 90.9
IIA 94 (46.3) 91.5
IIB 33 (16.3) 78.8
IIIA 13 (6.4) 67.7
IIIB 0 (0)
IIIC 8 (3.9) 25.0
Unknown 0 (0)
Nuclear grade 0.258
1 2 (1.0) 50.0
2 47 (23.2) 82.8
3 145 (71.4) 86.9
Unknown 9 (4.4) 77.8
Histologic grade 0.704
1 3 (1.5) 100.0
2 45 (22.2) 84.4
3 144 (70.9) 86.0
Unknown 11 (5.4) 72.7
EGFR (median: 7.0) 0.084
Low 104 (51.2) 90.3
High 99 (48.8) 79.8
ERBB2 (median: 9.0) 0.402
Low 102 (50.2) 88.2
High 101 (49.8) 82.1
ERBB3 (median: 7.2) 0.106
Low 102 (50.2) 90.2
High 101 (49.8) 80.1
ERBB4 (median: 1.3) 0.022
Low 102 (50.2) 90.1
High 101 (49.8) 80.2
ESR1 (median: 4.4) 0.689
Low 102 (50.2) 84.2




Table 2 Impact of baseline characteristics on patient prognosis
in the training cohort (N = 203) (Continued)
CMF1 86 (42.4) 90.7
FAC2 58 (28.6) 86.0
AC3 17 (8.4) 100.0
AC –T4 41 (20.2) 65.9
Unknown 1 (0.5) 100.0
Adjuvant RTx5 0.093
Yes 130 (64.0) 83.0
No 73 (36.0) 89.0
aInvasive ductal carcinoma, 1Cyclophosphamide /Methotrexate/Fluorouracil,
2Fluorouracil/Adriamycin/Cyclophosphamide, 3Adriamycin/Cyclophosphamide,
4Taxane, 5Radiotherapy
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significance (Additional file 1: Table S1 and Additional file
2: Figure S1). However, EGFR expression did not differ be-
tween TNBC and non-TNBC subtypes (p = 0.825). For
further survival analysis, we set the median expression
score of the five genes as the cut-off value to divide pa-
tients into low expression and high expression groups.
The association among the expression levels of the five
genes was analyzed by Pearson correlation analysis. We
found that ERBB2 expression in TNBC was positively
correlated with ERBB3 expression (Pearson r = 0.651,
p < 0.001), as well as with ERBB4 and ESR1 expression
(Pearson r = 0.414, p < 0.001) (Additional file 2: Figure
S2 and Additional file 1: Table S2).
Effect of ERBB4 expression on distant relapse-free
survival: univariate and multivariate analysis
Univariate analysis was conducted to investigate the ef-
fect of baseline characteristics on distant relapse-free
survival (Table 2). The 5-year DRFS rate in patients

















Fig. 3 Survival analysis in the training set (N = 203). a Kaplan-Meier survival curve for stage at diagnosis. b Kaplan-Meier survival curve for level
of ERBB4 expression. c Kaplan-Meier survival curve for level of ERBB4 expression in stage I/IIA (N = 149). d Kaplan-Meier survival curve for level
of ERBB4 expression in stage IIB/IIIA/IIIC (N = 54)
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respectively, in contrast to patients with stage IIB,
IIIA, and IIIC disease, who had 5Y DRFS of 78.8 %,
67.7 %, and 25.0 %, respectively (p < 0.001 by KM
survival analysis) (Table 2 and Fig. 3a). Of gene ex-
pressions, patients with high-ERBB4 TNBC had 5Y
DRFS of 80.2 %, compared with 90.1 % for those
with low ERBB4 expression (p = 0.022) (Table 2 and
Fig. 3b). We also found that patients who received
taxane-containing chemotherapy had poor prognosis.
However, we removed the variable of chemotherapy
regimen for further statistical analysis due to the
chemotherapy regimen was highly related to the stage of
disease (p < 0.001 by chi-square test) (Additional file 1:
Table S3).
In multivariate analysis using stage and ERBB4 gene
expression, both variables remained statistically significant
prognostic factors for DRFS: hazard ratio (HR) of DRFS
1.37 (95 % confidence interval [CI] 0.47-4.01 for stage IIA;
HR 3.28 (95 % CI 1.07-10.04) for stage IIB; HR 4.81, (95 %
CI 1.39-16.65), for stage IIIA, and HR 35.12, (95 % CI
9.62-128.27) for IIIC; HR 3.12 (95 % CI 1.42-6.87) for high
expression of ERBB4 (Table 3A).
Furthermore, we analyzed the relationship between
ERBB4 expression and DRFS according to stage. Because
previous analysis showed that patients with stages I or
IIA had similar survival rates whereas those with more
advanced stage had poor prognosis, we divided pa-
tients into an early-stage group (stage I/IIA) and an
advanced-stage group (stage IIB/IIIA/IIIC). In early-
stage breast cancer, ERBB4 expression did not affect
patient survival (5Y DRFS, low vs. high: 90.9 % vs.
90.2 %, p = 0.672) (Fig. 3c and Table 3B). However, for
patients diagnosed at advanced stage, those with high
ERBB4 expression had significantly poorer survival
outcomes than those with low ERBB4 expression (5Y
DRFS, low vs. high: 83.8 % vs. 55.2 %, p = 0.008)
(Fig. 3d and Table 3C).
We performed survival analysis on the validation
set. Patients in the validation set with high ERBB4-ex-
pressing breast cancer (cut-off value (log2 scale) = 1.3, the
same as that used for the training set) had worse DRFS
rates than those with low expression (5Y DRFS, low vs.
high: 69.4 % vs. 44.7 %, p = 0.053) (Fig. 4b). We also ob-
served this trend after dividing the patients into subgroups
of early stage and advanced stage, although it lacked statis-
tical significance (Fig. 4c and 4d). In addition, we analyzed
relationship between ERBB4 expression and patients’
prognosis in the control group. In contrast of TNBC, this
analysis showed that breast cancer with high ERBB4 ex-
pression had better prognosis than that with low ERBB4
expression (p = 0.003), as like as previous research pre-
senting that ERBB4 overexpression was good prognostic
indicator of ER positive and/or HER2 positive breast
cancer.
Effect of interaction between ERBB4 and ESR1 gene
expression on distant relapse-free survival in TNBC
To elucidate the interaction between ERBB4 and ESR1
gene expression, we analyzed the impact of ERBB4 and
ESR1 expression on DRFS in patients with TNBC.
We found that the group of high ERBB4 and low
ESR1 expression had the worst DRFS duration whereas
patients with low ERBB4 and low ESR1 expression had
the longest DRFS (p = 0.002) (Fig. 5a). This trend remained
but without statistical significance in the validation set
(Fig. 5b) and in subgroup analyses according to early-stage
and advanced-stage breast cancer (Additional file 2: Figure
S3A and 3B).
Prognostic value of the level of ERBB4 expression in
TNBC
ROC analysis was performed to evaluate the prognostic
value of ERBB4 expression level. According to multivari-
ate analysis, addition of ERBB4 expression level to TNM
stage enabled prediction of DRFS in both the training
Table 3 Effect of mRNA expression levels of ERBB4 and stage
on DRFS (multivariate analysis, Cox-regression)




IIA 1.37 0.47 – 4.01
IIB 3.28 1.07 – 10.04
IIIA 4.81 1.39 – 16.65
IIIC 35.12 9.62 – 128.27
ERBB4 (median: 1.3) 0.005
Low 1.0 NA
High 3.12 1.42 – 6.87
(B) Early stage (N = 149)
Stage 0.669
I 1.0 NA
IIA 1.37 0.43 – 3.77
ERBB4 (median: 1.3) 0.728
Low 1.0 NA
High 1.21 0.41 – 3.55
(C) Advanced stage (N = 54)
Stage <0.001
IIB 1.0 NA
IIIA 1.12 0.33 – 3.83
IIIC 35.71 6.73 – 189.65
ERBB4 (median: 1.3) 0.004
Low 1.0 NA
High 7.79 1.96 – 31.01
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and the validation set (Fig. 6). The results of ROC analysis
revealed that the value of ERBB4 expression strengthened
the predictive efficacy of TNM stage at diagnosis in both
the training and the validation set. In the training set, the
AUC of the expression level of ERBB4 with TNM stage
was 0.732 (p < 0.001), which is superior to the individual
predictive values of ERBB4 expression and TNM stage
(TNM stage: AUC 0.703, p < 0.001; ERBB4 expression:
AUC 0.607, p = 0.048) (Fig. 6a). We confirmed that this
trend was also evident in the validation set (TNM stage:
AUC 0.677, p = 0.005; ERBB4 expression: AUC 0.611,
p = 0.079; ERBB4 expression + TNM stage: AUC 0.711,
p < 0.001; Fig. 6b).
Discussion
In this study, we demonstrated the role of HER family
genes in TNBC and we suggested that the level of ERBB4
expression had potential prognostic value in TNBC.
Many studies on HER family gene expression in breast
cancer have previously been performed. Although most
of these studies involved breast cancer with EGFR or
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Fig. 4 Survival analysis in the validation set (N = 84). a Kaplan-Meier survival curve for stage at diagnosis. b Kaplan-Meier survival curve for level
of ERBB4 expression. c Kaplan-Meier survival curve for level of ERBB4 expression in stage I/IIA (N = 33). d Kaplan-Meier survival curve for level of
ERBB4 expression in stage IIB/IIIA/IIIC (N = 51)
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studies on the other HER family genes, including ERBB4.
These studies revealed that ERBB4 overexpression in
breast cancer is correlated with hormone receptor positiv-
ity [13, 20] and/or ERBB3 overexpression [31]. In addition,
ERBB4 overexpression was reported to be associated with
favorable prognosis in breast cancer patients [14], espe-
cially in cases of ER-positive [18, 31] and/or ERBB2-
amplified breast cancer [20, 32]. In contrast, Bieche et al.
showed that ERBB4-expression of breast cancer more
than that of normal breast tissue had extremely poor prog-
nosis compared with ERBB4-underexpressing breast can-
cer [17]. This study also included subgroup analysis that
identified ERBB4 overexpression as a marker for poor
prognosis in ER-negative breast cancer.
In our study, HER family gene expression was mea-
sured by nCounter expression assay. Because we used
formalin fixed paraffin embedded (FFPE) tissues which
collected 10 years ago, we needed a more sensitive tech-
nology for detection of gene expression to overcome the
weakness of IHC using old FFPE samples. Moreover, in
contrast to EGFR and ERBB2, immunohistochemistry of
ERBB3 and ERBB4 is not well established. Accordingly,
we chose to use the nCounter expression assay as the
method to measure gene expression rather than IHC.
Therefore, although this study was conducted on triple
negative breast cancer, we were able to detect RNA ex-
pression of ERBB2 and ESR1, and found a complex ex-
pression pattern among HER family members and the
ESR1 gene in TNBC. Moreover, our research showed
that ERBB4 expression could serve as a potential prog-
nostic factor when combined with pathologic stage in
TNBC, and confirmed this result in the validation set. In
a subgroup analysis, we found that the significance of
ERBB4 expression was more prominent in advanced-
stage TNBC.
Many tyrosine kinase inhibitors and monoclonal anti-
bodies against EGFR and ERBB2 RTK have successfully
been used as cancer drugs, for example cetuximab [33]
and panitumumab [34] for EGFR overexpression, and
afatinib [35] and dacomitinib as pan-HER inhibitors. In
the clinic, trastuzumab [8], pertuzumab [10], lapatinib
[11], and TDM-1[36] have been used in anti-HER2 ther-
apy for ERBB2-overexpressing breast cancer. However,
the biologic role of ERBB4 and its potential as a target
for cancer drugs has not been clearly identified. Some
studies have reported that ERBB4 regulated cell
differentiation and cell survival via the Mek/Erk pathway
[37, 38] and lapatinib inhibited the interaction of ERBB4
with EGFR and ERBB2 [39]. Therefore, lapatinib or a
MEK inhibitor might be an effective therapeutic option
in TNBC with high ERBB4 expression.
This study is the first study to demonstrate the impact
of ERBB4 expression on patient prognosis in TNBC.
Our study revealed that high expression of ERBB4 is an
independent prognostic factor in TNBC. Because this
study was performed in two independent groups, a train-
ing set and a validation set, the results of this study are
of high validity and reliability.
Our study did not include analysis of patient overall
survival. Because overall survival is influenced by pa-
tient’s characteristics like age, comorbidities as well as
breast cancer characteristics, DRFS might be more reli-
able indicator for breast cancer-specific survival rather
than overall survival.
In conclusion, our research suggests that ERBB4 ex-
pression is a valuable prognostic marker and may be
Log Rank P-value : .002
ERBB4 Low  ESR1 Low
ERBB4 High ESR1 Low
ERBB4 Low  ESR1 High
ERBB4 High ESR1 High
Log Rank P-value : .203
A B
Fig. 5 Survival analysis according to the level of ESR1 and ERBB4 expression. a Training set (N = 203). b Validation set (N = 84)
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A B
Stage  
AUC : .703, P-value : <001
ERBB4 expression  
AUC : .607, P-value : .048
ERBB4 expression  
AUC : .611, P-value : .079
Stage + ERBB4 expression
AUC : .711, P-value : <.001
Stage  
AUC : .677, P-value : .005
Stage + ERBB4 expression  
AUC : .732, P-value : <.001
Fig. 6 ROC analysis of predictive accuracy of stage and ERBB4 expression for DRFS. a Training set (N = 203). b Validation set (N = 84)
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useful to predict response to therapy for triple negative
breast cancer. Moreover, we expect that further clinical
trials on RTKs would benefit patients suffering from re-
fractory triple negative breast cancer with high ERBB4
expression.
Conclusions
Our research suggests that ERBB4 expression is a useful
prognostic marker and may be useful to predict response
to therapy for triple negative breast cancer.
Additional files
Additional file 1: Table S1. Baseline characteristics of patients’ cohort.
Table S2. The relationship among expression levels of ERBB family RTKs
in TNBC. Table S3. elationships between stage of disease and
chemotherapeutic agent. Table S4. Univariate analysis of baseline
characteristics affecting ERBB4 expression (N=203). (DOCX 29 kb)
Additional file 2: Figure S1. Box plots for the expression level of HER
family genes and ESR1 gene. (A) Training set (N = 203). (B) Validation set
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